A detailed history of Bank Of America Corp transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 308,051 shares of EWTX stock, worth $9.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
308,051
Previous 272,794 12.92%
Holding current value
$9.14 Million
Previous $4.91 Million 67.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.88 - $29.5 $559,881 - $1.04 Million
35,257 Added 12.92%
308,051 $8.22 Million
Q2 2024

Aug 14, 2024

BUY
$15.08 - $21.23 $3.3 Million - $4.65 Million
219,031 Added 407.4%
272,794 $4.91 Million
Q1 2024

May 15, 2024

SELL
$9.25 - $19.97 $78,671 - $169,844
-8,505 Reduced 13.66%
53,763 $980,000
Q4 2023

Feb 14, 2024

BUY
$5.51 - $12.1 $54,918 - $120,600
9,967 Added 19.06%
62,268 $681,000
Q2 2023

Aug 14, 2023

SELL
$5.71 - $10.29 $12,973 - $23,378
-2,272 Reduced 4.16%
52,301 $405,000
Q1 2023

May 12, 2023

BUY
$6.66 - $11.33 $13,273 - $22,580
1,993 Added 3.79%
54,573 $364,000
Q4 2022

Feb 10, 2023

BUY
$7.58 - $11.08 $298,250 - $435,964
39,347 Added 297.34%
52,580 $470,000
Q3 2022

Nov 14, 2022

SELL
$8.08 - $13.58 $215,614 - $362,382
-26,685 Reduced 66.85%
13,233 $130,000
Q2 2022

Aug 12, 2022

BUY
$5.67 - $9.87 $70,126 - $122,072
12,368 Added 44.89%
39,918 $317,000
Q1 2022

May 16, 2022

SELL
$9.1 - $18.97 $11,247 - $23,446
-1,236 Reduced 4.29%
27,550 $267,000
Q4 2021

Feb 08, 2022

BUY
$14.41 - $22.41 $375,322 - $583,690
26,046 Added 950.58%
28,786 $440,000
Q3 2021

Nov 15, 2021

BUY
$14.11 - $24.1 $38,661 - $66,034
2,740 New
2,740 $46,000

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $1.87B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.